Rhythm Biosciences share price lifts 5% on TGA news

The company is hoping to market and sell its cancer test kit in Australia this year.

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Rhythm Biosciences shares are rising again after a rollercoaster morning
  • The company has filed for Australian Register of Therapeutic Goods (ARTG) listing for its cancer test kit, ColoSTAT
  • Management is expecting a decision from the TGA within the next three to six months

The Rhythm Biosciences Ltd (ASX: RHY) share price is on a rollercoaster ride today following the company's latest release.

It surged 11.57% at market open today before falling to $1.18 — 2.5% lower than its previous close. However, the medical device company's shares have since bounced back and are now swapping hands for $1.27 — a 4.96% gain on the day.

For context, the All Ordinaries Index (ASX: XAO) is currently down 0.84%.

What did Rhythm announce?

The Rhythm Biosciences share price is bouncing around today after the company advised it has filed with the Australian Therapeutic Goods Administration (TGA) for the listing of ColoSTAT on the Australian Register of Therapeutic Goods (ARTG).

An experimental test kit, ColoSTAT is being developed as a low-cost, easy-to-use blood test to detect colorectal cancer.

The regulatory milestone would pave the way for the company to market and sell ColoSTAT within Australia.

Rhythm noted that the lifesaving cancer detection technology can potentially make a meaningful difference to millions of people around the world. 

With filing now completed, the TGA will assess Rhythm's ARTG listing submission and hopefully provide final approval to begin commercial activities.

The company anticipates the review process will be finalised within the next three to six months.

In the interim, Rhythm is focusing on executing across a number of key technical, administrative, and logistical activities for ColoSTAT. This includes supporting the pathway to market entry, both domestically and internationally, later this year.

Commenting on the news that appears to be driving the Rhythm Biosciences share price today, CEO and managing director Glenn Gilbert said:

This is an exciting time for all Rhythm stakeholders and indeed global cancer diagnostics markets. The team continues to diligently execute on our plans as we target ColoSTAT revenues in late CY22.

We are very close to being in a unique position to transform and revolutionise the colorectal diagnostics market with our lifesaving cancer detection technology.

Rhythm Biosciences share price snapshot

The Rhythm Biosciences share price has accelerated by 46% in the past 12 months, reflecting positive investor sentiment. The company's shares reached an all-time high of $2.08 in November, before treading lower.

At today's prices, Rhythm presides a market capitalisation of roughly $256.89 million, with approximately 214.08 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »